BCR-ABL transcript levels during dasatinib therapy. (A) All patients. (B) Patients who subsequently relapsed (red) or remained in remission at the last follow-up (blue). (C) Patients with p190 (red) or p210 (blue) forms of BCR-ABL. For display purposes, undetectable BCR-ABL transcript levels are plotted at 0.00001.